224 related articles for article (PubMed ID: 26257518)
1. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
4. Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies.
Liu Y; Shu L; Wu J
Leuk Lymphoma; 2015 Jun; 56(6):1863-8. PubMed ID: 25393677
[TBL] [Abstract][Full Text] [Related]
5. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
[TBL] [Abstract][Full Text] [Related]
6. Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway.
Ren H; Zhang C; Su L; Bi X; Wang C; Wang L; Wu B
Biochem Biophys Res Commun; 2015 Feb; 457(4):572-7. PubMed ID: 25603047
[TBL] [Abstract][Full Text] [Related]
7. [Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb].
Huang Y; Wu S; Zhang Y; Zi Y; Yang M; Guo Y; Zhang L; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1292-7. PubMed ID: 26739069
[TBL] [Abstract][Full Text] [Related]
8. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
9. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
10. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
11. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
12. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
[TBL] [Abstract][Full Text] [Related]
13. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
14. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
16. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
Zhang N; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
[TBL] [Abstract][Full Text] [Related]
17. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
18. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
[TBL] [Abstract][Full Text] [Related]
19. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Alduaij W; Ivanov A; Honeychurch J; Cheadle EJ; Potluri S; Lim SH; Shimada K; Chan CH; Tutt A; Beers SA; Glennie MJ; Cragg MS; Illidge TM
Blood; 2011 Apr; 117(17):4519-29. PubMed ID: 21378274
[TBL] [Abstract][Full Text] [Related]
20. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
Li L; Yang J; Wang J; Kopeček J
ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
